Jaguar Health Reports Second Quarter 2024 Financial Results
Jaguar Health has reported its Q2 2024 financial results, highlighting a 16% increase in combined net revenue to $2.72 million compared to Q1 2024. The revenue also saw a 2% growth compared to Q2 2023. Jaguar noted a decrease in various expenses and a significant decrease in net loss attributable to shareholders by 28% from $12.1 million in Q2 2023 to $9.5 million in Q2 2024. The company is set to launch its third prescription product, Gelclair, in October 2024 and is conducting pivotal phase 3 OnTarget trials of crofelemer for cancer therapy-related diarrhea. Additionally, an import permit for crofelemer was granted for trials in Abu Dhabi for pediatric patients with microvillus inclusion disease and short bowel syndrome.
The company will host an investor webcast on August 13, 2024, to discuss these updates.
Jaguar Health ha riportato i risultati finanziari del secondo trimestre del 2024, evidenziando un aumento del 16% nel fatturato netto combinato, che ha raggiunto $2,72 milioni rispetto al primo trimestre del 2024. Il fatturato ha registrato anche una crescita del 2% rispetto al secondo trimestre del 2023. Jaguar ha osservato una diminuzione delle varie spese e una significativa riduzione della perdita netta attribuibile agli azionisti, pari al 28%, passando da $12,1 milioni nel secondo trimestre del 2023 a $9,5 milioni nel secondo trimestre del 2024. L'azienda è pronta a lanciare il suo terzo prodotto prescritto, Gelclair, nell'ottobre del 2024 e sta conducendo prove cliniche pivotal di fase 3 OnTarget di crofelemer per la diarre collegate alla terapia oncologica. Inoltre, è stato concesso un permesso di importazione per il crofelemer per prove ad Abu Dhabi destinate a pazienti pediatrici con malattia da inclusione di microvilli e sindrome dell'intestino corto.
L'azienda ospiterà un webcast per gli investitori il 13 agosto 2024 per discutere questi aggiornamenti.
Jaguar Health ha informado sobre sus resultados financieros del segundo trimestre de 2024, destacando un incremento del 16% en los ingresos netos combinados, alcanzando $2,72 millones en comparación con el primer trimestre de 2024. Los ingresos también experimentaron un crecimiento del 2% en comparación con el segundo trimestre de 2023. Jaguar señaló una disminución en varios gastos y una reducción significativa de la pérdida neta atribuible a los accionistas del 28%, cayendo de $12,1 millones en el segundo trimestre de 2023 a $9,5 millones en el segundo trimestre de 2024. La empresa está lista para lanzar su tercer producto prescrito, Gelclair, en octubre de 2024 y está llevando a cabo ensayos clínicos pivotal de fase 3 OnTarget de crofelemer para la diarrea relacionada con la terapia del cáncer. Además, se concedió un permiso de importación para el crofelemer para ensayos en Abu Dhabi para pacientes pediátricos con enfermedad de inclusión de microvellos y síndrome de intestino corto.
La empresa organizará un webcast para inversionistas el 13 de agosto de 2024 para discutir estas actualizaciones.
재규어 헬스는 2024년 2분기 재무 결과를 보고하며, 1분기 대비 16%의 증가로 총 순 수익이 $2.72 백만에 도달했다고 밝혔습니다. 매출은 또한 2023년 2분기 대비 2% 성장을 기록했습니다. 재규어는 다양한 비용의 감소와 2023년 2분기 $12.1 백만에서 2024년 2분기 $9.5 백만으로 주주에게 귀속된 순손실이 28% 감소했다고 언급했습니다. 회사는 2024년 10월에 세 번째 처방 제품인 겔클레어를 출시할 예정이며, 암 치료와 관련된 설사를 위한 크로펠레머의 중요한 3상 OnTarget 임상 시험을 진행 중입니다. 또한, 미세융모 포함 질환 및 단장 증후군을 가진 소아 환자를 위한 아부다비의 임상 시험을 위해 크로펠레머의 수입 허가가 승인되었습니다.
회사는 2024년 8월 13일 투자자 웹캐스트를 개최하여 이러한 업데이트를 논의할 예정입니다.
Jaguar Health a annoncé ses résultats financiers du deuxième trimestre 2024, mettant en évidence une augmentation de 16% des revenus nets combinés, atteignant 2,72 millions de dollars par rapport au premier trimestre 2024. Les revenus ont également connu une croissance de 2% par rapport au deuxième trimestre 2023. Jaguar a noté une diminution de diverses dépenses et une réduction significative de la perte nette attribuable aux actionnaires de 28%, passant de 12,1 millions de dollars au deuxième trimestre 2023 à 9,5 millions de dollars au deuxième trimestre 2024. La société s'apprête à lancer son troisième produit sur prescription, Gelclair, en octobre 2024 et mène des essais pivot de phase 3 sur le crofelemer pour la diarrhée liée à la thérapie anticancéreuse. De plus, un permis d'importation pour le crofelemer a été accordé pour des essais à Abu Dhabi pour des patients pédiatriques atteints de la maladie d'inclusion des microvillosités et du syndrome de l'intestin court.
La société organisera un webinaire pour les investisseurs le 13 août 2024 afin de discuter de ces mises à jour.
Jaguar Health hat seine Finanzzahlen für das zweite Quartal 2024 veröffentlicht und hebt einen 16%-Anstieg der kombinierten Nettoumsätze auf 2,72 Millionen Dollar im Vergleich zum ersten Quartal 2024 hervor. Der Umsatz verzeichnete auch ein 2%-Wachstum im Vergleich zum zweiten Quartal 2023. Jaguar stellte einen Rückgang verschiedener Ausgaben und einen signifikanten Rückgang des den Aktionären zurechenbaren Nettoverlusts von 28% fest, von 12,1 Millionen Dollar im zweiten Quartal 2023 auf 9,5 Millionen Dollar im zweiten Quartal 2024. Das Unternehmen plant, sein drittes verschreibungspflichtiges Produkt, Gelclair, im Oktober 2024 auf den Markt zu bringen und führt wichtige Phase-3-OnTarget-Studien zu Crofelemer bei durch Krebstherapie bedingter Diarrhöe durch. Darüber hinaus wurde eine Importgenehmigung für Crofelemer für Studien in Abu Dhabi für pädiatrische Patienten mit Mikrovillus-Inklusionskrankheit und Kurzdarmsyndrom erteilt.
Das Unternehmen wird am 13. August 2024 ein Webcast für Investoren veranstalten, um diese Aktualisierungen zu besprechen.
- Jaguar Health's combined net revenue increased by 16% QoQ to $2.72 million.
- Net loss attributable to common shareholders decreased by 28%, from $12.1 million to $9.5 million.
- Planned commercial launch of Gelclair in October 2024.
- Import permit granted for crofelemer in trial for pediatric MVID and SBS patients in Abu Dhabi.
- Jaguar Health reported a net loss of $9.5 million in Q2 2024.
- Non-GAAP recurring EBITDA showed a net loss of $8.8 million.
Insights
Jaguar Health's Q2 2024 results show mixed signals. The 16% quarter-over-quarter revenue growth to
The planned launch of Gelclair in October 2024 could potentially boost revenues, but its impact remains uncertain. The company's focus on rare disease development and the OnTarget trial for cancer therapy-related diarrhea could be pivotal for future growth, but these are long-term prospects with no immediate financial impact.
Investors should closely monitor the company's cash burn rate and future financing needs, as continued losses may necessitate additional capital raising.
The ongoing analysis of the OnTarget trial for crofelemer in cancer therapy-related diarrhea (CTD) is crucial. The focus on breast and lung cancer patients is strategically sound, given the high prevalence of these cancers globally. However, investors should be cautious as the FDA discussion outcome is uncertain.
The proof-of-concept studies for rare diseases like microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure are promising avenues for expansion. The granted import permit for Abu Dhabi is a positive step, potentially accelerating the research process.
While these developments are encouraging, it's important to note that clinical trials, especially in rare diseases, carry significant risks and often require substantial time and resources before yielding commercial results. The company's ability to manage multiple clinical programs simultaneously will be critical for long-term success.
The combined net Q2 2024 revenue of approximately
Company to complete analysis of full data for first and second 12-week periods of pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) in support of FDA discussion; Jaguar to explore possible approval pathway for crofelemer in breast and lung cancer based on phase 3 results
Jaguar planning to begin commercial launch in October 2024 for Gelclair®, the company's third prescription product
Import permit for crofelemer granted for independent, investigator-initiated proof-of-concept trial in Abu Dhabi in pediatric patients for the rare and orphan disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure
REMINDER: Jaguar to host investor webcast Tuesday, August 13th at 8:30 a.m. Eastern regarding Q2 2024 financials and company updates; Click here to register for webcast
SAN FRANCISCO, CA / ACCESSWIRE / August 13, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported its consolidated second-quarter 2024 financial results and provided Company updates.
The combined net revenue for the Company's crofelemer prescription products, Mytesi® and Canalevia®-CA1, and the Company's non-prescription products, was approximately
Jaguar, with strong leadership and participation from Jaguar family companies Napo Pharmaceuticals and Napo Therapeutics, is supporting investigator-initiated proof-of-concept (POC) studies of crofelemer for the rare disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure in the US, EU, and Middle East/North Africa (MENA) regions, with results expected by the end of 2024 and throughout 2025. The import permit for crofelemer for Abu Dhabi for the POC study in pediatric patients with MVID or SBS with intestinal failure has been granted. In accordance with the guidelines of specific EU countries, published data from clinical investigations in such rare diseases could support early patient access to crofelemer for these debilitating conditions in those countries.
Lisa Conte, Jaguar's president and CEO, said, "Our paramount near-term activities are our planned October 2024 commercial launch of the FDA-approved oral mucositis prescription product Gelclair® in the U.S., progressing our rare disease development business, and our ongoing analysis of full data for the first and second 12-week stages of our pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD). As announced, we are collaborating with our clinical and scientific advisers to evaluate the significance of the clinically meaningful results identified in patients with breast and lung cancer in the initial data from OnTarget, as we plan to engage in discussions with the FDA to explore the possible pathway of approval to make crofelemer available to breast and lung cancer patients for CTD."
According to the World Health Organization, in 2022 breast cancer was the most common cancer in women in 157 countries out of 185, with 2.3 million women diagnosed with breast cancer globally.1 Lung cancer is the most common cancer worldwide, with 2,480,675 new cases of lung cancer in 2022. It is the most common cancer in men and the second most common in women.2
2024 SECOND QUARTER COMPANY FINANCIAL RESULTS:
Net Mytesi Revenue: The combined net revenue for Mytesi was approximately
$2.64 million in the second quarter of 2024, representing an increase of approximately15% over the combined net revenue in the first quarter of 2024, which totaled approximately$2.35 million , and an increase of1% over the combined net revenue for the second quarter of 2023, which totaled approximately$2.62 million .Mytesi Prescription Volume: Mytesi prescription volume increased in the second quarter of 2024 compared to the first quarter of 2024 by
5.2% . Prescriptions decreased by0.4% in the second quarter of 2024 compared to the second quarter of 2023. Prescription volume differs from invoiced sales volume, which reflects, among other factors, varying buying patterns among specialty pharmacies in the closed network as they manage their inventory levels.Neonorm™: Revenues for the non-prescription Neonorm products were minimal for the second quarters of 2024 and 2023.
| Three Months Ended |
|
|
|
|
|
|
|
| ||||||||
Financial Highlights |
| June 30, |
|
|
|
|
|
|
|
| |||||||
(in thousands, except per share amounts) |
| 2024 |
|
| 2023 |
|
| $ change |
|
| % change |
|
| ||||
Net product revenue |
| $ | 2,720 |
|
| $ | 2,676 |
|
|
| 44 |
|
|
| 2 | % |
|
Loss from operations |
| $ | (7,198 | ) |
| $ | (8,102 | ) |
|
| 904 |
|
|
| -13 | % |
|
Net loss attributable to common shareholders |
| $ | (9,492 | ) |
| $ | (12,150 | ) |
|
| 2,658 |
|
|
| -28 | % |
|
Net loss per share, basic and diluted |
| $ | (4.04 | ) |
| $ | (41.35 | ) |
|
| 37 |
|
|
| -924 | % |
|
Cost of Product Revenue: Total cost of product revenue decreased by approximately
$70,000 from$0.50 million for the quarter ended June 30, 2023 compared to$0.43 million for the quarter ended June 30, 2024Research and Development: The R&D expense decreased by
$0.6 million , from$4.3 million for the quarter ended June 30, 2023 to$3.7 million during the same quarter in 2024, primarily due to the winding down of activities related to the phase 3 OnTarget clinical trial, regulatory activities for the trial, and the Company's initiatives for rare disease product development.Sales and Marketing: The Sales and Marketing expense decreased by approximately
$0.1 million , from$1.6 million for the quarter ended June 30, 2023 to$1.5 million during the same quarter in 2024. Direct marketing fees and expenses decreased due to continued savings associated with the utilization of a more cost-effective patient support services vendor, other Mytesi marketing initiatives, as well as decreased stock-based compensation, and commission expenses.General and Administrative: The G&A expense decreased by
$0.1 million , from$4.4 million for the quarter ended June 30, 2023, to$4.3 million during the same quarter in 2024, due to decreases in personnel and benefits, rent and lease, stock-based compensation, travel and other expenses. However, this decrease is offset by an increase in consulting, audit, tax and accounting services, and public company expenses.Loss from Operations: Loss from operations decreased by
$0.9 million , from$8.1 million in the quarter ended June 30, 2023 to$7.2 million during the same period in 2024.Net Loss: Net loss attributable to common shareholders decreased by approximately
$2.6 million , from$12.1 million in the quarter ended June 30, 2023 to$9.5 million in the same period in 2024. In addition to the loss from operations:Interest expense decreased by
$3.3 million from ($0.11) million in the quarter ended June 30, 2024 versus$3.5 million for the same period in 2023, primarily due to certain debt instruments being accounted for using the fair value option. The lower interest expense was offset with a higher loss on change in fair value of debt instruments.Change in fair value of financial instrument and hybrid instrument designated at FVO increased by
$1.0 million from a loss of$1.8 million in the three months ended June 30, 2024 compared to a loss of$0.8 million for the same period in 2023 primarily due to fair value adjustments in liability classified warrants and notes payable designated at FVO.
Non-GAAP Recurring EBITDA: Non-GAAP recurring EBITDA for the second quarter of 2024 and the second quarter of 2023 were a net loss of
$8.8 million and$7.7 million , respectively.
| Three Months Ending |
| ||||||
| June 30, |
| ||||||
(in thousands) |
| 2024 |
|
| 2023 |
| ||
| (unaudited) |
| ||||||
Net loss attributable to common shareholders: |
| $ | (9,492 | ) |
| $ | (12,150 | ) |
Adjustments: |
|
|
|
|
|
|
|
|
Interest expense |
|
| (108 | ) |
|
| 3,453 |
|
Property and equipment depreciation |
|
| 17 |
|
|
| 20 |
|
Amortization of intangible assets |
|
| 430 |
|
|
| 484 |
|
Share-based compensation expense |
|
| 387 |
|
|
| 529 |
|
Non-GAAP EBITDA |
|
| (8,766 | ) |
|
| (7,665 | ) |
Non-GAAP Recurring EBITDA |
| $ | (8,766 | ) |
|
| (7,665 | ) |
Note Regarding Use of Non-GAAP Measures
The Company supplements its condensed consolidated financial statements presented on a GAAP basis by providing non-GAAP EBITDA and non-GAAP recurring EBITDA, which are considered non-GAAP under applicable SEC rules. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which Company management assesses and operates the business. These non-GAAP financial measures are not in accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for, or superior to, measures of financial performance in conformity with GAAP.
The Company defines non-GAAP EBITDA as net loss before interest expense and other expense, depreciation of property and equipment, amortization of intangible assets, share-based compensation expense and provision for or benefit from income taxes. The Company defines non-GAAP Recurring EBITDA as non-GAAP EBITDA adjusted for certain non-recurring revenues and expenses. Company management believes that non-GAAP EBITDA and non-GAAP Recurring EBITDA are meaningful indicators of Jaguar's performance and provide useful information to investors regarding the Company's results of operations and financial condition.
Participation Instructions for Webcast
When: Tuesday, August 13, 2024, at 8:30 AM Eastern Time
Participant Registration & Access Link: Click Here
Replay Instructions for Webcast
Replay of the webcast on the investor relations section of Jaguar's website: (click here)
About Crofelemer
Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program at makecancerlessshitty.com and on X, Facebook & Instagram
About Mytesi®
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (
See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
About Gelclair®
INDICATIONS
GELCLAIR® has a mechanical action indicated for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis (may be caused by chemotherapy or radiation therapy), irritation due to oral surgery, traumatic ulcers caused by braces or ill-fitting dentures, or disease. Also, indicated for diffuse aphthous ulcers.
IMPORTANT SAFETY INFORMATION
Do not use GELCLAIR if there is a known or suspected hypersensitivity to any of its ingredients.
No adverse effects have been reported in clinical trials, although postmarketing reports have included infrequent complaints of burning sensation in the mouth.
If GELCLAIR is swallowed accidentally, no adverse effects are anticipated.
If no improvement is seen within 7 days, a physician should be consulted.
You are encouraged to report negative side effects of prescription medical products to the FDA.
Visit www.fda.gov/safety/medwatch, call 1-855-273-0468 or fill-in the form at this link.
Please see full Prescribing Information at:
https://gelclair.com/assets/Gelclair_PI_Decemeber_2021.pdf
Important Safety Information About Canalevia®-CA1
For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
See full Prescribing Information at Canalevia.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that it will host an investor webcast on August 13, 2024, the Company's expectation that it will begin the commercial launch in October 2024 for Gelclair, Jaguar's expectation that the Company may engage in discussions with the FDA after evaluating the significance of the clinical outcome signals from the OnTarget trial, Jaguar's expectation that an approval pathway may exist to make crofelemer available to breast and lung cancer patients for CTD, the Company's expectation that results from investigator-initiated and IND proof-of-concept studies of crofelemer for MVID and SBS with intestinal failure will be available by the end of 2024 and throughout 2025, and the Company's expectation, that in accordance with the guidelines of specific EU countries, published data from clinical investigations of crofelemer in MVID and SBS could support early patient access to crofelemer for these conditions in those countries. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
1 https://www.who.int/news-room/fact-sheets/detail/breast-cancer
2 https://www.wcrf.org/cancer-trends/lung-cancer-statistics/
CONTACT:
hello@jaguar.health
SOURCE: Jaguar Health, Inc.
View the original press release on accesswire.com
FAQ
What was Jaguar Health's Q2 2024 revenue?
How did Jaguar Health's Q2 2024 revenue compare to Q1 2024?
What was Jaguar Health's net loss in Q2 2024?
When is Jaguar Health planning to launch Gelclair?
What are the phase 3 OnTarget trials for?